Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis

• Main Authors: Cheepsattayakorn A., Cheepsattayakorn R.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-84863919123&partnerID=40&md5=1a1e9de81938354c2bc8ba1bdcf07dae; http://cmuir.cmu.ac.th/handle/6653943832/3894
• Institution: Chiang Mai University

A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide. © 2012 Bentham Science Publishers.